Skip to main content

Cutting cost and time – HCV immunoassay predicts clinical response rate to antiviral treatment

Ref-Nr: TA-B76124


Kurzfassung

  • Antiviral treatment for chronic HCV infections are very effective but cost-intense
  • Immunological blood marker-based test predicts clinical response to antiviral drugs
  • Individualized shorter treatment duration significantly reduces long-term cost

Hintergrund

Each year, 3-4 million people become infected with the hepatitis C virus (HCV). In 30% of cases, the virus clears within 6 months of infection without treatment. However, an estimated 71 million people globally develop a chronic course often resulting in cirrhosis or liver cancer1. For these patients, the introduction of all-oral direct-acting antiviral (DAA) therapy has revolutionized treatment and life options with a 95% cure rate. However, their high treatment costs not only largely limit access to therapy but also poses a severe burden on the healthcare budget with total costs currently as high as $150.000 per patient. However, response to DAA treatment can vary considerably between patients in terms of HCV RNA negativity. With the potential to identify the response outcome for patients before treatment, shorter and individualized courses of DAA therapy are made possible and possess a significant benefit toward reducing overall treatment costs.


Bilder & Videos


Lösung

Here, we present a method to predict clinical response rate to DAA treatment of patients with chronic HCV infection by virtue of early viral control. DAA treatment is known to alter distribution of CD8+ memory T cell subsets. Prior to starting the cost-intense DAA treatment, analysis of peripheral blood by flow cytometry for frequency of CD8+ TEM lymphocytes divides patients into “fast” and “slow” responders to DAA therapy. Measured frequencies of CD3+ and naive CD8+ T cells correctly classified 82.6 % of patients as “fast” (HCV RNA-negative by 4 weeks) or “slow”2. With a false-positive rate to predict a fast response of only 9.1 %, this method can reliably shorten treatment duration.


Vorteile

  • Cost-effective approach to shorter treatment: under $100 in less than 4 h
  • Highly standardized flow cytometry-based assay with commercially available kits
  • Individually-tailored assay principle can be extend to other analytical methods or biomarkers

Bayerische Patentallianz GmbH


089 5480177-0
kontakt@baypat.de
www.baypat.de
Adresse
Destouchesstr. 68
80796 München



Entwicklungsstand

Machbarkeit


Kontakt | Geschäftsstelle

TransferAllianz e. V.
Christiane Bach-Kaienburg
(Geschäftsstellenleiterin)

c/o PROvendis GmbH
Schloßstr. 11-15
D-45468 Mülheim an der Ruhr